BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 33324406)

  • 21. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resveratrol and Pterostilbene Inhibit SARS-CoV-2 Replication in Air-Liquid Interface Cultured Human Primary Bronchial Epithelial Cells.
    Ter Ellen BM; Dinesh Kumar N; Bouma EM; Troost B; van de Pol DPI; van der Ende-Metselaar HH; Apperloo L; van Gosliga D; van den Berge M; Nawijn MC; van der Voort PHJ; Moser J; Rodenhuis-Zybert IA; Smit JM
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight.
    Akilesh SM; J R; Palanisamy D; Wadhwani A
    Curr Pharm Biotechnol; 2021; 22(2):192-199. PubMed ID: 32867651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein.
    Chen Y; Wu Y; Chen S; Zhan Q; Wu D; Yang C; He X; Qiu M; Zhang N; Li Z; Guo Y; Wen M; Lu L; Ma C; Guo J; Xu W; Li X; Li L; Jiang S; Pan X; Liu S; Tan S
    J Virol; 2022 Dec; 96(24):e0124522. PubMed ID: 36468859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry.
    Duarte RRR; Copertino DC; Iñiguez LP; Marston JL; Bram Y; Han Y; Schwartz RE; Chen S; Nixon DF; Powell TR
    Mol Med; 2021 Sep; 27(1):105. PubMed ID: 34503440
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in SARS-CoV-2.
    Smith E; Davis-Gardner ME; Garcia-Ordonez RD; Nguyen TT; Hull M; Chen E; Baillargeon P; Scampavia L; Strutzenberg T; Griffin PR; Farzan M; Spicer TP
    SLAS Discov; 2020 Dec; 25(10):1152-1161. PubMed ID: 33043784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.
    Blaess M; Kaiser L; Sommerfeld O; Csuk R; Deigner HP
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening of Botanical Drugs against SARS-CoV-2 Entry Reveals Novel Therapeutic Agents to Treat COVID-19.
    Cao J; Liu Y; Zhou M; Dong S; Hou Y; Jia X; Lan X; Zhang Y; Guo J; Xiao G; Wang W
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2.
    Ku KB; Shin HJ; Kim HS; Kim BT; Kim SJ; Kim C
    J Microbiol Biotechnol; 2020 Dec; 30(12):1843-1853. PubMed ID: 33203821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoV.
    Milewska A; Chi Y; Szczepanski A; Barreto-Duran E; Dabrowska A; Botwina P; Obloza M; Liu K; Liu D; Guo X; Ge Y; Li J; Cui L; Ochman M; Urlik M; Rodziewicz-Motowidlo S; Zhu F; Szczubialka K; Nowakowska M; Pyrc K
    J Virol; 2021 Jan; 95(4):. PubMed ID: 33219167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential inhibitors of SARS-CoV-2: recent advances.
    Jamalipour Soufi G; Iravani S
    J Drug Target; 2021 Apr; 29(4):349-364. PubMed ID: 33210953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic.
    Won JH; Lee H
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33371468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. iPSC screening for drug repurposing identifies anti-RNA virus agents modulating host cell susceptibility.
    Imamura K; Sakurai Y; Enami T; Shibukawa R; Nishi Y; Ohta A; Shu T; Kawaguchi J; Okada S; Hoenen T; Yasuda J; Inoue H
    FEBS Open Bio; 2021 May; 11(5):1452-1464. PubMed ID: 33822489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication.
    Chu J; Xing C; Du Y; Duan T; Liu S; Zhang P; Cheng C; Henley J; Liu X; Qian C; Yin B; Wang HY; Wang RF
    Nat Metab; 2021 Nov; 3(11):1466-1475. PubMed ID: 34580494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Attacking COVID-19 Progression Using Multi-Drug Therapy for Synergetic Target Engagement.
    Coban MA; Morrison J; Maharjan S; Hernandez Medina DH; Li W; Zhang YS; Freeman WD; Radisky ES; Le Roch KG; Weisend CM; Ebihara H; Caulfield TR
    Biomolecules; 2021 May; 11(6):. PubMed ID: 34071060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches.
    Watashi K
    Biochem Biophys Res Commun; 2021 Jan; 538():137-144. PubMed ID: 33272566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug Discovery of Small Molecules for the Treatment of COVID-19: A Review on Clinical Studies.
    Goel B; Bhardwaj N; Tripathi N; Jain SK
    Mini Rev Med Chem; 2021; 21(12):1431-1456. PubMed ID: 33371848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.
    Yuan S; Chan JFW; Chik KKH; Chan CCY; Tsang JOL; Liang R; Cao J; Tang K; Chen LL; Wen K; Cai JP; Ye ZW; Lu G; Chu H; Jin DY; Yuen KY
    Pharmacol Res; 2020 Sep; 159():104960. PubMed ID: 32473310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.